HK1243329A1 - 谷氨酸草酰乙酸转氨酶1(got1)、其制剂、产生方法及用途 - Google Patents

谷氨酸草酰乙酸转氨酶1(got1)、其制剂、产生方法及用途 Download PDF

Info

Publication number
HK1243329A1
HK1243329A1 HK18102801.5A HK18102801A HK1243329A1 HK 1243329 A1 HK1243329 A1 HK 1243329A1 HK 18102801 A HK18102801 A HK 18102801A HK 1243329 A1 HK1243329 A1 HK 1243329A1
Authority
HK
Hong Kong
Prior art keywords
got1
methods
preparations
oxaloacetate transaminase
glutamate oxaloacetate
Prior art date
Application number
HK18102801.5A
Other languages
English (en)
Chinese (zh)
Inventor
David Mirelman
Aharon Rabinkov
Angela Ruban
Ghil Jona
Eli Hazum
Vladas BUMELIS
Nerijus MAKAUSKAS
Saule SUDZIUVIENE
Elena NARMONTAITE
Original Assignee
Yeda Research And Development Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research And Development Co., Ltd. filed Critical Yeda Research And Development Co., Ltd.
Publication of HK1243329A1 publication Critical patent/HK1243329A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1096—Transferases (2.) transferring nitrogenous groups (2.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C07K1/303—Extraction; Separation; Purification by precipitation by salting out
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y206/00—Transferases transferring nitrogenous groups (2.6)
    • C12Y206/01—Transaminases (2.6.1)
    • C12Y206/01001—Aspartate transaminase (2.6.1.1), i.e. aspartate-aminotransferase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
HK18102801.5A 2015-03-31 2016-03-31 谷氨酸草酰乙酸转氨酶1(got1)、其制剂、产生方法及用途 HK1243329A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562140492P 2015-03-31 2015-03-31
US62/140,492 2015-03-31
PCT/IL2016/050346 WO2016157190A1 (en) 2015-03-31 2016-03-31 Glutamate oxaloacetate transaminase 1 (got1), preparations and methods of generating same and uses thereof

Publications (1)

Publication Number Publication Date
HK1243329A1 true HK1243329A1 (zh) 2018-07-13

Family

ID=55795016

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18102801.5A HK1243329A1 (zh) 2015-03-31 2016-03-31 谷氨酸草酰乙酸转氨酶1(got1)、其制剂、产生方法及用途

Country Status (11)

Country Link
US (1) US20180071369A1 (cg-RX-API-DMAC10.html)
EP (1) EP3277308A1 (cg-RX-API-DMAC10.html)
JP (1) JP2018511325A (cg-RX-API-DMAC10.html)
KR (1) KR20170132293A (cg-RX-API-DMAC10.html)
CN (1) CN107771217A (cg-RX-API-DMAC10.html)
AU (1) AU2016242298A1 (cg-RX-API-DMAC10.html)
BR (1) BR112017021016A2 (cg-RX-API-DMAC10.html)
CA (1) CA2979309A1 (cg-RX-API-DMAC10.html)
HK (1) HK1243329A1 (cg-RX-API-DMAC10.html)
RU (1) RU2017135552A (cg-RX-API-DMAC10.html)
WO (1) WO2016157190A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018229764A1 (en) 2017-06-13 2018-12-20 Yeda Research And Development Co. Ltd. Treatment of advanced or progressive multiple sclerosis
RU2712193C1 (ru) * 2018-07-27 2020-01-24 Общество с ограниченной ответственностью научно-технический центр "БиоКлиникум" (ООО НТЦ "БиоКлиникум") Способ лечения поражения нервной системы с помощью рекомбинантной глутаматоксалоацетаттрансаминазы
US11740211B2 (en) * 2020-01-31 2023-08-29 Waters Technologies Corporation LC/MS adduct mitigation by vapor deposition coated surfaces
CN116143898B (zh) * 2023-01-30 2026-03-24 翌圣生物科技(上海)股份有限公司 骨形态发生蛋白bmp-2重组蛋白、编码基因及其原核表达方法
CN118147225A (zh) * 2024-03-25 2024-06-07 华中农业大学 黄颡鱼去sumo化修饰体系及其构建方法和应用
WO2026139625A1 (en) 2024-12-26 2026-07-02 Alternative Gene Expression S.L. Glutamate-oxaloacetate transaminase (got1) – fc (fragment crystallizable) fusion proteins

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
DE60318014T2 (de) * 2002-01-07 2008-11-27 Lifesensors, Inc. Verfahren und zusammensetzungen für die proteinexpression und reinigung
CA2494348C (en) * 2002-08-01 2014-04-08 Yeda Research And Development Co. Ltd. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
GB0315248D0 (en) * 2003-06-30 2003-08-06 Hoffmann La Roche HCV regulated protein expression
WO2006069610A2 (en) * 2004-07-02 2006-07-06 Metanomics Gmbh Process for the production of fine chemicals
EP2096177A3 (en) * 2004-12-17 2010-01-13 Metanomics GmbH Process for the production of lutein
EP1836214A4 (en) 2004-12-30 2009-01-21 Lifesensors Inc COMPOSITIONS, METHODS, AND KITS FOR IMPROVING PROTEIN EXPRESSION, SOLUBILITY, AND ISOLATION
CA2670014A1 (en) * 2006-11-22 2008-11-20 Emory University Production of anti-microbial peptides
CA2674304C (en) * 2006-12-29 2016-02-23 Lifesensors, Inc. Methods and compositions for enhanced protein expression and purification
ES2534936T3 (es) * 2010-08-02 2015-04-30 Ratiopharm Gmbh Método para producir y purificar una sialiltransferasa soluble activa
WO2012159782A1 (en) * 2011-05-24 2012-11-29 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune High affinity sumo traps

Also Published As

Publication number Publication date
CA2979309A1 (en) 2016-10-06
RU2017135552A3 (cg-RX-API-DMAC10.html) 2019-07-24
JP2018511325A (ja) 2018-04-26
US20180071369A1 (en) 2018-03-15
RU2017135552A (ru) 2019-04-30
CN107771217A (zh) 2018-03-06
WO2016157190A1 (en) 2016-10-06
KR20170132293A (ko) 2017-12-01
BR112017021016A2 (pt) 2018-07-03
AU2016242298A1 (en) 2017-10-19
EP3277308A1 (en) 2018-02-07

Similar Documents

Publication Publication Date Title
EA202190906A1 (ru) Рекомбинантное получение препаратов пептидов коллагена и их применение
MX2024004646A (es) Proteinas de union de cadena unica de fragmento variable cd3.
EA201991168A1 (ru) Белок, связывающий простатический специфический мембранный антиген
AU2017263237A1 (en) GDF15 fusion proteins and uses thereof
MX2019004810A (es) Ácidos ribonucleicos mensajeros para aumentar respuestas inmunes y métodos para usarlos.
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
WO2018083087A3 (en) Binding proteins
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
SA518390954B1 (ar) لقاحات علاجية لفيروس الورم الحليمي البشري 18
WO2017218624A8 (en) Influenza virus hemagglutinin proteins and uses thereof
BR112019008351A2 (pt) imunoglobulinas e usos das mesmas
HRP20211601T1 (hr) Rekombinantni proteini bez fenilalanina (phe) za liječenje fenilketonurije
EP4374913A3 (en) Novel human serum albumin mutant
WO2016107818A8 (en) Compositions and methods for protein glycosylation
MX2016007429A (es) Mezcla de peptidos.
HK1248714A1 (zh) Ras蛋白的突变的片段
WO2017041001A3 (en) Insulin immunoglobulin fusion proteins
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
MX387764B (es) Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos.
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
BR112015032556A2 (pt) Proteína matriz (m) modificada de um vírus da estomatite vesicular (vsv); sequência de nucleotídeos que codifica uma proteína matriz modificada de um vírus da estomatite vesicular; vírus da estomatite vesicular recombinante (rvsv); vacina; vacina de combinação de preparação e reforço; kit; peptídeo isolado; sequências de nucleotídeos isoladas; uso da vacina; uso da vacina de combinação de preparação e reforço; método para induzir uma resposta imunológica em um indivíduo
BR112018072592A2 (pt) vetor de vacina de levedura que inclui polipeptídeos imunoestimulantes e antigênicos, e métodos de uso dos mesmos
CY1124079T1 (el) Αποτελεσματικη επιλεκτικοτητα των ανασυνδυασμενων πρωτεϊνων
BR112017021016A2 (pt) preparação de proteína, composição farmacêutica, proteína de fusão, polinucleotídeo isolado, estrutura de ácido nucleico, método para tratamento de doença ou condição associada ao excesso de glutamato, e método de purificação de um polipeptídeo
WO2019103512A3 (ko) 목적 단백질의 발현 효율을 증진시키기 위한 신규한 펩타이드 및 이를 포함하는 융합 단백질